Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor

摘要

The Present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF-α inhibitor.